| Literature DB >> 30271430 |
Gamil A Al-Hazmi1,2, Khlood S Abou-Melha1, Nashwa M El-Metwaly3,4, Kamel A Saleh5.
Abstract
A series of perimidineEntities:
Year: 2018 PMID: 30271430 PMCID: PMC6151213 DOI: 10.1155/2018/7176040
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Scheme 1Synthesis of perimidine compounds 3a–e.
Figure 11H·NMR of L1 ligand (as example).
Figure 2Mass spectra of L1 and L4 ligands.
Figure 3(a) Structures of perimidine ligands (L1–5). (b) Optimized structures of five perimidine ligands.
Significant analytical and physical data of perimidine compounds and their VO(II) complexes.
| Compounds (formula weight) (calcd./found) | Color | Elemental analysis (%) calcd. (found) | ||||
|---|---|---|---|---|---|---|
| C | H | N | SO4/Cl | V | ||
| ( | Dark brown | 76.91 (76.90) | 4.65 (4.66) | 14.35 (14.35) | — | — |
| ( | Dark brown | 40.88 (40.88) | 2.74 (2.73) | 7.63 (7.65) | 26.16 (26.16) | 13.87 (13.88) |
| ( | Dark brown | 74.27 (74.27) | 4.79 (4.79) | 13.32 (13.31) | — | — |
| ( | Dark green | 39.91 (39.90) | 3.09 (3.10) | 7.16 (7.17) | 24.55 (24.54) | 13.02 (13.03) |
| ( | Dark brown | 68.96 (68.95) | 3.93 (3.93) | 16.08 (16.09) | — | — |
| ( | Dark green | 38.52 (38.52) | 2.46 (2.46) | 8.99 (8.97) | 24.65 (24.66) | 13.07 (13.05) |
| ( | Dark brown | 70.67 (70.66) | 4.03 (4.02) | 13.19 (13.18) | 8.34 (8.35) | — |
| ( | Dark green | 39.05 (39.05) | 2.49 (2.48) | 7.29 (7.28) | 24.99 (25.02)/4.61 (4.63) | 13.25 (13.26) |
| ( | Dark brown | 70.67 (70.68) | 4.03 (4.05) | 13.19 (13.18) | 8.34 (8.35) | — |
| ( | Dark brown | 37.30 (37.31) | 2.88 (2.88) | 6.96 (6.95) | 23.87 (23.88)/4.40 (4.41) | 12.66 (12.67) |
Significant IR spectral bands (cm−1) of perimidine compounds and their VO(II) complexes.
| Compounds |
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| ( | 3155 | 1473 | 1618 | 1518 | — | — | — | — | — | — |
| ( | 3110, 3350 | 1470 | 1596 | 1514 | 1420 | 1142 | 765, 670 | 966 | 588 | 476 |
| ( | 3177 | 1470 | 1597 | 1508 | —- | — | — | — | — | — |
| ( | 3100, 3372 | 1447 | 1592 | 1502 | 1411 | 1146 | 765, 697 | 1074 | 572 | 515 |
| ( | 3150 | 1473 | 1620 | 1538 | — | — | — | — | — | — |
| ( | 3105, 3382 | 1447 | 1616 | 1517 | 1411 | 1179 | 743, 697 | 966 | 600 | 508 |
| ( | 3160 | 1474 | 1614 | 1518 | — | — | — | — | — | — |
| ( | 3100, 3420 | 1471 | 1624 | 1510 | 1434 | 1150 | 755, 637 | 985 | 610 | 550 |
| ( | 3150 | 1473 | 1620 | 1518 | — | — | — | — | — | — |
| ( | 3054, 3384 | 1446 | 1616 | 1512 | 1368 | 1140 | 754, 689 | 1074 | 589 | 508 |
Electronic transitions of perimidine compounds and their VO(II) complexes.
| Compounds |
| d-d transition bands (cm−1) | Intraligand and charge transfer (cm−1) |
|---|---|---|---|
| ( | — | — | 31,746; 26,316; 23,923; 18,868 |
| ( | 1.66 | 15,290; 12800 | 35,714; 29,412; 25,641; 24,272; 17,857 |
| ( | — | — | 38,168; 28,249; 23,810; 19,048 |
| ( | 1.68 | 15,393; 12750 | 37,037; 30,769; 26,316; 23,256; 17,544 |
| ( | — | — | 36,364; 30,303; 26,316; 23,810; 19,157 |
| ( | 1.66 | 15,873; 12830 | 37,037; 28,571; 26,667; 18,182 |
| ( | — | — | 31,746; 25,974; 18,587 |
| ( | 1.67 | 15,385; 12,800 | 35,714; 30,303; 25,974; 24,390; 17,857 |
| ( | — | — | 31,250; 26,316; 24,390; 18,182 |
| ( | 1.65 | 15,873; 12780 | 35,714; 30,769; 25,000; 23,256; 18,868 |
Figure 4Geometry optimization of VO(II)-perimidine complexes (a–e, respectively).
Figure 5ESR spectrum of L1 + VO(II)complex.
Spin Hamiltonian parameters of all VO(II) complexes (A and p x10−4).
| Complex |
|
|
|
|
|
|
|
|
|
|
2
|
2
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ( | 1.93 | 1.96 | 1.95 | 167 | 115.57 | 66 | 99.67 | 1.71 | 117.52 | 0.796 | −0.843 | −1.981 | 1.959 | 0.9357 |
| ( | 1.94 | 1.97 | 1.96 | 170 | 114.12 | 71 | 104.00 | 1.93 | 115.19 | 0.861 | −0.724 | −1.512 | 1.490 | 0.9435 |
| ( | 1.92 | 1.96 | 1.95 | 168 | 114.28 | 69 | 105.67 | 1.95 | 115.19 | 0.865 | −0.961 | −1.985 | 1.964 | 0.9243 |
| ( | 1.94 | 1.98 | 1.97 | 171 | 113.45 | 73 | 105.67 | 2.79 | 114.00 | 0.895 | −0.727 | −1.055 | 1.033 | 0.9395 |
| ( | 1.93 | 1.97 | 1.96 | 171 | 112.86 | 72 | 105.00 | 2.24 | 115.19 | 0.869 | −0.841 | −1.515 | 1.494 | 0.9318 |
Figure 6X-ray diffraction pattern of high crystalline ligand.
Estimated TG data of perimidine compounds and all VO(II) complexes.
| Compound | Steps | Temp. range (°C) | Decomposed | Weight loss; calcd. (found %) |
|---|---|---|---|---|
| L1 | 1st | 45.1–120.5 | -[C6H6 + N2] | 27.18 (27.16) |
| 2nd | 122.2–410.1 | -[C6H5 + CO] | 26.92 (26.95) | |
| 3rd | 410.3–670.2 | -[C8H7N2] | 33.59 (33.54) | |
| Residue | 4C | 12.31 (12.35) | ||
| [(VO)2 (SO4)2 (L1)]H2O | 1st | 80.3–120.3 | -[H2O + SO4] | 15.53 (15.55) |
| 2nd | 120.6–391.7 | -[SO4 + C6H6 + N2] | 27.53 (27.55) | |
| 3rd | 391.9–798.8 | -[C19H12N2] | 36.53 (36.50) | |
| Residue | V2O3 | 20.41 (20.40) | ||
| L2 | 1st | 65.6–156.1 | -[C6H5OCH3] | 25.72 (25.71) |
| 2nd | 156.6–299.9 | -[C6H5 + CO + N2] | 31.66 (31.69) | |
| 3rd | 301.0–663.2 | -[C9H7N2] | 34.05 (33.89) | |
| Residue | 3C | 8.57 (8.71) | ||
| [(VO)2 (SO4)2 (L2)]2H2O | 1st | 42.1–135.1 | -[2H2O + 2SO4] | 29.16 (29.16) |
| 2nd | 136.1–270.1 | -[C6H5OCH3 + N2] | 17.40 (17.29) | |
| 3rd | 271.0–485.4 | -[C6H5] | 9.85 (9.94) | |
| 4th | 485.6–797.9 | -[C13H7N2] | 24.43 (24.45) | |
| Residue | V2O3 | 19.15 (19.16) | ||
| L3 | 1st | 63.66–230.51 | -[C6H6 + NO2] | 28.50 (27.90) |
| 2nd | 231.21–410.11 | -[C7H5 + CO + N2] | 33.33 (33.31) | |
| 3rd | 410.52–650.64 | -[C11H6N2] | 38.16 (38.79) | |
| [(VO)2 (SO4)2 (L3)]H2O | 1st | 79.2–140.6 | -[H2O + SO4] | 14.63 (14.62) |
| 2nd | 141.9–278.9 | -[SO4 + C6H5 + CO] | 25.81 (25.78) | |
| 3rd | 279.1–479.5 | -[NO2 + C6H6 + N2] | 19.52 (19.53) | |
| 4th | 480.11–798.8 | -[C12H6N2] | 22.86 (22.90) | |
| Residue | V2O2 | 17.18 (17.17) | ||
| L4 | 1st | 64.65–145.46 | -[C6H5Cl + CO + N2] | 39.68 (39.68) |
| 2nd | 145.68–326.78 | -[C6H5 + N2] | 24.74 (24.75) | |
| 3rd | 330.12–680.23 | -[C12H7] | 35.58 (35.57) | |
| [(VO)2 (SO4)2 (L4)]H2O | 1st | 69.1–256.1 | -[H2O + C6H5Cl + SO4] | 29.48 (29.65) |
| 2nd | 256.9–484.1 | -[SO4 + CON2 + C6H5] | 29.80 (29.81) | |
| 3rd | 484.6–789.4 | -[C10H7N2] | 20.18 (19.98) | |
| Residue | V2O2 + 2C | 20.54 (20.56) | ||
| L5 | 1st | 62.3–169.6 | -[C6H5 + N2] | 24.74 (24.71) |
| 2nd | 160.1–371.9 | -[C6H5Cl + CO + N2] | 39.68 (39.59) | |
| 3rd | 372.6–666.8 | -[C9H7] | 27.10 (27.19) | |
| Residue | 3C | 8.48 (8.51) | ||
| [(VO)2 (SO4)2 (L5)]3H2O | 1st | 42.1–266.3 | -[3H2O + C6H5Cl] | 20.70 (20.71) |
| 2nd | 266.38–482.5 | -[2SO4 + CON2 + C6H5] | 40.41 (40.61) | |
| 3rd | 482.9–793.5 | -[C8H7N2] | 16.29 (16.36) | |
| Residue | V2O2 + 4C | 22.60 (22.32) |
Figure 7Hammett's relation between the effect of p-substituent (σR) and intrinsic binding constants (K b) of the ligands.
Figure 8(a) Frontier molecular orbitals of HOMO(1)and LUMO(2) pictures of perimidine ligands. (b) Frontier molecular orbitals of HOMO(1) and LUMO(2) pictures of VO(II)-perimidine complexes (A–E, respectively).
Energy parameters (eV) using the DFT/B3LYP method of optimized structures.
| Compound |
|
| ( |
|
|
|
|
|
| ϭ |
|---|---|---|---|---|---|---|---|---|---|---|
| L1 | −0.17417 | −0.07574 | −0.0984 | 0.09843 | 0.124955 | −0.12496 | 0.049215 | 0.024608 | 0.158628 | 20.31900843 |
| L1 + VO(II) | −0.20433 | −0.19545 | −0.0089 | 0.00888 | 0.19989 | −0.19989 | 0.00444 | 0.00222 | 4.499551 | 225.2252252 |
| L2 | −0.17142 | −0.07426 | −0.0972 | 0.09716 | 0.12284 | −0.12284 | 0.04858 | 0.02429 | 0.155307 | 20.58460272 |
| L2 + VO(II) | −0.20163 | −0.19237 | −0.0093 | 0.00926 | 0.197 | −0.197 | 0.00463 | 0.002315 | 4.191037 | 215.9827214 |
| L3 | −0.21252 | −0.05654 | −0.156 | 0.15598 | 0.13453 | −0.13453 | 0.07799 | 0.038995 | 0.11603 | 12.82215669 |
| L3 + VO(II) | −0.21881 | −0.21008 | −0.0087 | 0.00873 | 0.214445 | −0.21445 | 0.004365 | 0.002183 | 5.267658 | 229.0950745 |
| L4 | −0.25291 | −0.05654 | −0.1964 | 0.19637 | 0.154725 | −0.15473 | 0.098185 | 0.049093 | 0.121912 | 10.18485512 |
| L4 + VO(II) | −0.20433 | −0.19545 | −0.0089 | 0.00888 | 0.19989 | −0.19989 | 0.00444 | 0.00222 | 4.499551 | 225.2252252 |
| L5 | −0.17808 | −0.0842 | −0.0939 | 0.09388 | 0.13114 | −0.13114 | 0.04694 | 0.02347 | 0.183188 | 21.30379207 |
| L5 + VO(II) | −0.19719 | −0.16607 | −0.0311 | 0.03112 | 0.18163 | −0.18163 | 0.01556 | 0.00778 | 1.060073 | 64.26735219 |
Figure 9Hammett's relation between the effect of p-substituent (σR) and energy gaps (δE) of ligands and their VO(II) complexes.
Considerable bond lengths, charges, dipole moment (D), oscillator strength (ʄ), and excitation energies (E).
| Compound | O19 | N11 | N15 | N16 | C18–O19 | C12–N11 | C14–N15 | N15–N16 | V1 | V2 |
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L1 | −0.415473 | −0.555221 | −0.349927 | −0.275635 | 1.224561 | 1.384229 | 1.287795 | 1.366391 | — | — | 5.1769 | 567.81 | 0.0316 |
| L1 + VO(II) | −0.410181 | −0.282766 | −0.316313 | −0.248429 | — | — | — | — | 0.933201 | 0.929331 | 11.5667 | 16513.7 | 0.003 |
| L2 | −0.410237 | −0.555363 | −0.348134 | −0.275746 | — | — | — | — | — | — | 6.4963 | 576.26 | 0.0403 |
| L2 + VO(II) | −0.420038 | −0.397120 | −0.322648 | −0.250261 | — | — | — | — | 0.927552 | 0.915069 | 3.5504 | 31387.7 | 0.0008 |
| L3 | −0.416751 | −0.044378 | −0.050930 | 0.113237 | 1.317259 | 2.076019 | 1.772715 | 1.281712 | — | — | 5.3595 | 7613.39 | 0.002 |
| L3 + VO(II) | −0.414856 | −0.387699 | −0.320321 | −0.254947 | 0.955124 | 0.952544 | 16.6899 | 17266.3 | 0.0032 | ||||
| L4 | −0.313357 | −0.358945 | −0.031267 | −0.294059 | 1.223609 | 1.404653 | 1.286454 | 1.367672 | — | — | 4.4684 | 315.92 | 0.4055 |
| L4 + VO(II) | −0.410181 | −0.282766 | −0.316313 | −0.248429 | — | — | — | — | 0.933201 | 0.929331 | 11.5667 | 16513.7 | 0.003 |
| L5 | −0.354631 | −0.480428 | −0.209492 | −0.312115 | 1.224058 | 1.384450 | 1.286411 | 1.367122 | — | — | 3.9661 | 600.17 | 0.043 |
| L5 + VO(II) | −0.405024 | −0.408894 | −0.304735 | −0.210573 | — | — | — | — | 0.905245 | 0.730601 | 8.9706 | 20988.6 | 0.002 |
QSAR computation for optimized structures of perimidine compounds.
| Function | L1 | L2 | L3 | L4 | L5 |
|---|---|---|---|---|---|
| Surface area (approx.) (Å2) | 425.73 | 488.36 | 496.79 | 464.04 | 465.53 |
| Surface area (grid) (Å2) | 623.02 | 661.15 | 661.91 | 644.29 | 642.82 |
| Volume (Å3) | 1060.57 | 1138.87 | 1134.04 | 1105.99 | 1105.72 |
| Hydration energy (kcal/mol) | −8.29 | −9.97 | −17.83 | −8.00 | −8.02 |
| Log P | 2.53 | 1.53 | −1.64 | 2.31 | 2.31 |
| Reactivity (Å3) | 132.87 | 139.25 | 138.92 | 137.59 | 137.59 |
| Polarizability (Å3) | 45.32 | 47.80 | 47.62 | 47.25 | 47.25 |
| Mass (amu) | 390.44 | 420.47 | 436.45 | 424.89 | 424.89 |
Docking energy values (kcal/mol) of perimidine compounds (HL) and protein receptors complexes.
| Ligands | p | Receptor | Est. free energy of binding | Est. inhibition constant ( | vdW + bond + desolving energy | Electrostatic energy | Total intercooled energy | Frequency | Interacting surface |
|---|---|---|---|---|---|---|---|---|---|
| L1 | 10.96 | 4c3p | −7.92 | 1.57 | −9.29 | −0.06 | −9.34 | 30% | 859.778 |
| 3bch | +355.37 | — | +349.42 | +0.06 | +349.48 | 10% | 665.36 | ||
| 4zdr | −4.72 | 345.45 | −5.97 | −0.05 | −6.02 | 20% | 723.695 | ||
| L2 | 10.96 | 4c3p | −7.75 | 2.09 | −9.13 | −0.13 | −9.26 | 10% | 983.377 |
| 3bch | +490.76 | — | +473.39 | +0.00 | +473.39 | 10% | 662.71 | ||
| 4zdr | −4.32 | 686.85 | −5.97 | −0.02 | −5.99 | 20% | 758.018 | ||
| L3 | 10.95 | 4c3p | +647.56 | — | +644.74 | +0.01 | +644.75 | 10% | 718.318 |
| 3bch | +709.10 | — | +699.61 | −0.05 | +699.56 | 10% | 661.43 | ||
| 4zdr | −4.66 | 385.21 | −6.46 | +0.07 | −6.39 | 10% | 621.389 | ||
| L4 | 10.96 | 4c3p | −7.28 | 4.62 | −8.57 | −0.03 | −8.60 | 20% | 929.747 |
| 3bch | +552.25 | — | +549.59 | −0.03 | +549.56 | 30% | 710.605 | ||
| 4zdr | −4.67 | 376.04 | −6.13 | −0.19 | −6.32 | 20% | 595.541 | ||
| L5 | 10.95 | 4c3p | −8.41 | 683.74 | −9.81 | −0.00 | −9.81 | 20% | 925.161 |
| 3bch | +663.87 | — | +661.94 | +0.01 | +661.95 | 10% | 703.598 | ||
| 4zdr | −4.84 | 284.49 | −6.39 | +0.04 | −6.35 | 10% | 690.838 |
Figure 10Interacting protein-inhibitor complexes (a) L1, (b) L2, (c) L3, (d) L4, and (e) L5 with 4zdr receptor (a–e, respectively).
Figure 11Interacting complexes hp plot for (a) L1, (b) L2, (c) L3, (d) L4, and (e) L5 with 4zdr receptor (a–e, respectively).
IC50 of some tested compounds against liver (HepG2), breast (MCF-7), and colon (HCT116) cancer cell lines.
| Cell type | IC50 ( | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| L1 | VO(II)-L1 | L2 | VO(II)-L2 | L3 | VO(II)-L3 | L4 | VO(II)-L4 | L5 | VO(II)-L5 | Doxorubicin | |
| MCF-7 | 19.68 | 23.06 | 25.92 | 93.92 | 15.50 | >100 | 24.96 | 3.42 | 11.44 | >100 | 0.60 |
| HepG2 | 19.79 | 19.94 | 27.23 | 55.67 | 11.01 | >100 | 28.25 | 1.27 | 9.91 | >100 | 0.34 |
| HCT116 | 19.15 | 22.93 | 13.27 | 95.17 | 15.53 | >100 | 26.24 | 1.66 | 23.30 | >100 | 0.39 |
Figure 12Dose response curves of perimidine ligands against MCF-7 (a), HCT116 (b), and HepG2 (c) cancer cells.